Entrada Therapeutics, Inc. (TRDA)
10.81
+0.22
(+2.08%)
USD |
NASDAQ |
Dec 11, 16:00
10.82
+0.01
(+0.09%)
After-Hours: 20:00
Entrada Therapeutics Cash from Investing (Quarterly): 49.11M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Janux Therapeutics, Inc. | 8.306M |
| NovaBay Pharmaceuticals, Inc. | 0.00 |
| Palatin Technologies, Inc. | 0.00 |
| Theriva Biologics, Inc. | -0.019M |
| Oragenics, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -28.31M |
| Cash from Financing (Quarterly) | 0.008M |
| Free Cash Flow | -129.80M |
| Free Cash Flow Per Share (Quarterly) | -0.6787 |
| Free Cash Flow to Equity (Quarterly) | -25.80M |
| Free Cash Flow to Firm (Quarterly) | -28.14M |
| Free Cash Flow Yield | -28.77% |